BeiGene Ltd. (ONC) saw its stock price surge 5.03% in pre-market trading on Wednesday, following the release of its impressive third-quarter financial results for 2025. The biotechnology company's performance marked a significant turnaround, transitioning from losses to substantial profits.

According to the financial report, BeiGene's revenue for the first three quarters of 2025 reached RMB27.595 billion, representing a robust year-on-year growth of 44.2%. More notably, the company reported a net profit attributable to shareholders of RMB1.139 billion, successfully reversing the losses incurred during the same period last year. The non-GAAP net profit stood at RMB969 million, further underlining the company's financial recovery.

Investors were particularly encouraged by BeiGene's basic earnings per share of RMB0.81. The company attributed its improved performance to strong product revenue growth and enhanced operational efficiency through effective cost management strategies. This positive financial outlook has clearly resonated with the market, driving the significant uptick in BeiGene's stock price as traders react to the company's newfound profitability and growth prospects.